-
-
ZOKINVY
- QTY 30
- 50 MG
- Capsule
- Near 77381
LONAFARNIB (loe na far nib) treats genetic conditions that cause rapid aging, such as progeria. It works by reducing the buildup of proteins in the body that speed up aging. This reduces or delays symptoms, such as heart problems.
Change Location
Set Price Drop Alert for:
ZOKINVY
- QTY 30
- 50 MG
- Capsule
What does Supply mean?
If your selected quantity is intended to last longer than one month, please recheck the price using the 3-months supply option. In some cases, the estimated drug price may vary depending on the supply duration.
More Ways to Save On:
ZOKINVY
- QTY 30
- 50 MG
- Capsule
You may find alternative ways to save with this medication. Talk to your pharmacist about the potential option(s) noted below.
Medicine Chest
ZOKINVY Lifestyle Interactions
-
Lonafarnib 50mg, Oral capsule
• Interaction: Grapefruit juice• Severity: Severe• Notes for Consumers: Do not take Grapefruit juice or grapefruit-containing foods and Lonafarnib together without talking to your health care provider. Taking these together may increase the risk of serious side effects.• Notes for Professionals: Advise patients to avoid grapefruit juice or grapefruit-containing foods during treatment with lonafarnib; concurrent use may increase the exposure of lonafarnib and the risk of adverse effects. Lonafarnib is a sensitive CYP3A4 substrate and grapefruit juice is a strong CYP3A4 inhibitor. Coadministration with another strong CYP3A4 inhibitor increased the exposure of lonafarnib by 425%. -
Lonafarnib 50mg, Oral capsule
• Interaction: Cannabis• Severity: Major• Notes for Consumers: Discuss cannabis use with your care team. The effects of cannabis may be altered if used with your medication. Call emergency services right away if you experience slow or shallow breathing, shortness of breath, feeling faint, dizziness, confusion, or trouble staying awake.• Notes for Professionals: Advise patients to avoid cannabis use during lonafarnib treatment. Concomitant use may alter the exposure of some cannabinoids and increase the risk for adverse reactions. The cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are CYP3A substrates and lonafarnib is a strong CYP3A inhibitor. Concomitant use of a cannabinoid product containing THC and CBD at an approximate 1:1 ratio with another strong CYP3A inhibitor increased THC, 11-OH-THC, and CBD peak exposures by 1.3-, 3-, and 1.9-fold respectively.
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.
